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Abstract
Many human cancers exhibit elevated prostaglandin (PG) levels
due to upregulation of cyclooxygenase-2 (COX-2), a key enzyme in
eicosanoid biosynthesis. COX-2 over-expression has been
observed in about 40% of cases of invasive breast carcinoma and
at a higher frequency in preinvasive ductal carcinoma in situ tumors,
Extensive pharmacologic and genetic evidence implicates COX
enzymes in neoplasia. Epidemiologic analyses demonstrate a
protective effect of COX-inhibiting nonsteroidal anti-inflammatory
drugs with respect to human cancer. Complementary experimental
studies have established that both conventional nonsteroidal anti-
inflammatory drugs and selective COX-2 inhibitors suppress
mammary tumor formation in rodent breast cancer models.
Furthermore, knocking out Cox-2 reduces mammary tumorigenesis
and angiogenesis, and, conversely, transgenic COX-2 over-expres-
sion induces tumor formation. The utility of COX/PG signaling as a
target for chemoprevention has been established by randomized
controlled clinical trials. However, these studies also identified
increased cardiovascular risk associated with use of selective
COX-2 inhibitors. Thus, current efforts are directed toward
identifying safer approaches to antagonizing COX/PG signaling for
cancer prevention and treatment, with a particular focus on PGE2
regulation and signaling, because PGE2 is a key pro-tumorigenic
prostanoid.
Introduction
The past few years have witnessed intense interest in the role
played by the cyclooxygenase (COX) family of prostaglandin
(PG) synthases in cancer. Upregulation of the inducible
isoform COX-2 has been identified in many human cancers
and precancerous lesions. Initially recognized in the context
of colorectal cancer, COX-2 over-expression has also been
detected in approximately 40% of cases of human breast
carcinoma as well as in preinvasive ductal carcinoma in situ
(DCIS) lesions. Furthermore, epidemiologic analyses suggest
a protective effect of COX inhibitory drugs with respect to
both colon and breast cancer. Together, these observations
have stimulated widespread enthusiasm for COX-2 as a
molecular target for cancer prevention.
Substantial data support the validity of COX-2 as an anti-
cancer target. Transgenic COX-2 over-expression drives
mammary tumor formation, and, conversely, knocking out
Cox-2 reduces tumor formation in rodent models of intestinal,
breast, and skin cancer. Consistent with these genetic
studies, selective COX-2 inhibitors (COXibs) have proven to
be effective in suppressing experimental tumorigenesis.
Furthermore, several recently reported randomized clinical
trials have shown that COXibs significantly reduce the
incidence of colorectal adenomas in humans. Dismayingly,
these trials also identified an increased risk for cardiovascular
events associated with COXib use, suggesting that COXibs
may not be sufficiently safe for general use as cancer chemo-
preventive agents. Nevertheless, the demonstrated role of
COX/PG signaling in neoplasia identifies this pathway as an
important anticancer target. Therefore, it behooves us to
identify alternative components of the COX/PG signaling
pathway, antagonism of which will achieve protection
comparable to that afforded by COXibs but with minimal
collateral toxicity.
Here, I review the data implicating COX/PG signaling in
breast cancer, and consider alternative approaches to
suppressing this pathway that may have clinical utility.
Cyclooxygenases, prostaglandins, and cancer
The COX family of enzymes comprises two members. COX-1
(more properly PTGS1 [PG-endoperoxide synthase 1]) is
generally considered to be ubiquitously expressed, whereas
COX-2 (or  PTGS2 [PG-endoperoxide synthase 2]) is
constitutively expressed in only a limited range of tissues,
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including placenta, brain, and kidney [1,2]. However, COX-2
upregulation is elicited by numerous stimuli, including
cytokines, growth factors and oncogenes, and is both an
important component of the inflammatory response as well as
an early response gene. Both COX enzymes catalyze the
conversion of arachidonic acid to PGG2 and subsequently to
PGH2, which acts as a substrate for multiple isomerases that
are individually responsible for the generation of eicosanoid
products, including PGE2, prostacyclin (PGI2), and throm-
boxane A2 (Figure 1). COX-derived prostanoids contribute to
many bodily functions, including hemostasis, platelet
aggregation, kidney and gastric function, and several female
reproductive processes [1,2]. Eicosanoids are also key
mediators of pain, fever, and inflammation. Hence, COX
enzymes are the targets for common painkillers of the non-
steroidal anti-inflammatory drug (NSAID) class. Inhibitors that
are selective for COX-2 have also been developed as anti-
inflammatory agents, with the goal of minimizing the gastro-
intestinal complications associated with traditional NSAIDs.
Aberrant activation of COX/PG signaling is widespread in
human neoplasia [1,3]. The first indication of this was
provided by the detection of elevated PG levels in cancer
samples. Subsequently, it became apparent that cancer-
associated increases in PG synthesis correlated with COX-2
over-expression. COX-2 upregulation is particularly striking in
colon cancer. Thus, COX-2 protein is virtually undetectable in
normal colonic mucosa, but more than 85% of colorectal
adenocarcinomas have elevated COX-2 levels [1,4]. Similarly,
COX-2 is undetectable in normal breast tissue by immuno-
histochemistry, but it is over-expressed in about 40% of
human breast carcinomas (discussed below). These and
similar data from cancers of other organ sites have identified
COX-2 upregulation as a common event in human cancer,
and thus they suggest that COX-2 may play a role in
tumorigenesis.
A protumorigenic role for COX enzymes and COX-derived
PGs has also been inferred from epidemiologic analyses.
Several studies have identified an inverse relationship
between colon cancer incidence and use of NSAIDs, which
inhibit COX activity [4]. Similar data are also available for
breast cancer [5-12]. Discrepant findings in some reports
may reflect the fact that human breast cancers do not
uniformly over-express COX-2. Nevertheless, epidemiologic
data broadly support a protumorigenic role for COX enzymes
in breast cancer.
Cyclooxygenase-2 expression in breast cancer
Elevated COX-2 protein levels have been detected
immunohistochemically in approximately 40% of invasive
breast carcinomas, with individual studies reporting
frequencies ranging from 17% to 84% [13-26]. COX-2
protein is predominantly confined to the tumor epithelium,
with negligible expression in normal epithelium (Figure 2). In
contrast, COX-1 appears to be ubiquitously expressed in
mammary tissues [21,25]. Cox-2 upregulation has also been
detected in rodent mammary tumors, including those from
both transgenic mouse and carcinogen-dependent breast
cancer models [27-31]. Consistent with human observations,
Cox-2 protein is present in epithelial cells in rodent tumors
[30,31]. These localization data provide a marked contrast to
those from colorectal cancer studies, which have identified
substantial COX-2 expression in the stromal component of
intestinal adenomas [32]. It remains to be determined
whether stromal COX-2 expression plays a significant role in
breast neoplasia.
COX-2 over-expression in human breast cancers correlates
with several parameters that are characteristic of aggressive
breast disease, including large tumor size, high grade, high
proliferation, hormone receptor negative status, and over-
expression of HER2 (human epidermal growth factor
receptor 2; also called neu and c-ERBB2) [13,24,26,33].
Consistent with these findings, Ristimaki and colleagues [26]
Figure 1
Eicosanoid metabolism and signaling. Cyclooxygenase (COX) enzymes
convert arachidonic acid to the intermediate prostaglandin PGG2, and
thence to PGH2. Subsequent enzymatic steps, catalyzed by specific
isomerases, generate a variety of eicosanoid products. Thromboxane
(TX) A2 and prostacyclin (PGI2), products of platelet COX-1 and
endothelial COX-2, respectively, are thought to play opposing roles in
cardiovascular biology. Most important in the context of epithelial
tumorigenesis, PGE2 is generated from PGH2 through the action of PGE
synthases. Signaling downstream of PGE2 is initiated via interaction of
PGE2 with cognate PGE2 receptors EP1 to EP4. PGE2 signaling can be
terminated via catabolism mediated by 15-hydroxyprostaglandin
dehydrogenase (15-PGDH). Elevated PGE2 levels in neoplastic tissues
can thus be a consequence of COX-2 over-expression, PGE synthase
modulation, and/or loss of 15-PGDH expression.Page 3 of 9
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have identified an inverse relationship between COX-2
protein levels and disease-free survival (Figure 3). Because
HER2/neu can induce COX-2 transcription  in vitro, the
correlation between HER2/neu and  COX-2 expression in
breast carcinomas probably reflects a causal relationship
[13,24,26,33,34]. Interestingly, both HER2/neu and COX-2
are expressed at higher frequencies in DCIS (50% to 60%
and 63% to 85%, respectively), which again is suggestive of
a potential interrelationship. The high frequency of COX-2
over-expression in DCIS, a common precursor to invasive
breast cancer, identifies COX/PG signaling as a potentially
useful target for preventing progression of DCIS to invasive
disease [13,17,20,21,23,35,36]. Intriguingly, COX-2 expres-
sion has also been detected in focal regions of normal breast
in association with silencing of CDKN2A (p16INK4a), suggest-
ing that COX-2 upregulation may be a very early event in
breast neoplasia [37].
Cyclooxygenase-2 contributes to breast
cancer: experimental evidence
Since  Cox-2 is over-expressed in mammary tumors from
rodent breast cancer models, these animals provide useful
experimental systems in which to evaluate the role of COX
enzymes. Numerous studies have shown that experimental
breast cancer can be suppressed by inhibiting Cox activity
with either conventional NSAIDs or COXibs [38,39].
Furthermore, genetic ablation of Cox-2 decreases mammary
tumor formation [40]. Strikingly, transgenic over-expression of
COX-2 is sufficient to induce mammary neoplasia in
multiparous animals, providing direct evidence of the in vivo
oncogenicity of COX-2 [41]. Thus, animal-based approaches
have played a pivotal role in definitively establishing that
COX-2 contributes to breast cancer.
Cyclooxygenase inhibitors suppress experimental
breast cancer
The efficacy of COX inhibitors as anticancer agents has been
tested in a variety of animal models (for detailed reviews, see
Howe [38], Howe and coauthors [39], Reddy [42], and
Corpet and Pierre [43]). The ability of conventional NSAIDs
such as indomethacin and flurbiprofen to suppress carcinogen-
induced mammary tumor formation was first demonstrated
more than 20 years ago. More recently, following the
development of COXibs, these agents have also been tested
in animal breast cancer models. Several COXibs, including
celecoxib, nimesulide and rofecoxib, have demonstrated
chemopreventive efficacy in chemical carcinogenesis models
[30,38,39,44,45]. COX inhibitors also reduce the growth rate
of implanted tumors, suggesting potential therapeutic utility.
Chemically-induced tumors tend to be hormone-dependent,
providing a valuable model for human breast cancers, of
which approximately two-thirds are estrogen dependent.
Additionally, we considered it relevant to evaluate COXib
efficacy in an estrogen receptor (ER)-negative model, because
several groups had reported a correlation between COX-2
over-expression and ER-negative status [13,16,24,26].
HER2/neu transgenic mice offer a compelling test system,
because the tumors not only lack ER but also express both
HER2/neu and  Cox-2, thus recapitulating the relationship
between HER2/neu and COX-2 in human breast cancer.
Using HER2/neu transgenic mice, both we and others have
shown that ER-negative tumor formation is significantly
delayed by celecoxib administration [29,46]. These data
suggest that antagonism of COX/PG signaling could be
useful with respect to both ER-negative and HER2/neu-over-
expressing breast cancers. The demonstrated chemo-
preventive efficacy of NSAIDs and COXibs in animal models
is consistent with epidemiologic studies that show reduced
breast cancer incidence in association with NSAID use [5-12].
Mammary tumorigenesis is reduced in 
cyclooxygenase-2-null mice
While the anticancer effects of conventional NSAIDs and
COXibs strongly implicate COX enzymes in breast cancer,
numerous COX-independent effects have been ascribed to
NSAIDs [47,48]. Therefore, we also used a complementary
Available online http://breast-cancer-research.com/content/9/4/210
Figure 2
COX-2 expression in human breast tumors. Cyclooxygenase (COX)-2 protein has been detected in human breast biopsies in both (a) ductal
carcinoma in situ and (b) infiltrating mammary carcinoma using immunohistochemistry on formalin-fixed tissue sections. Representative data are
reproduced from [21] by permission of Wiley-Liss Inc., a subsidiary of John Wiley and Sons Inc. (Copyright (2000) American Cancer Society.)genetic approach to definitively address the involvement of
COX-2 in mammary tumorigenesis. Mice with targeted
disruption of the Cox-2 gene were first utilized to establish
the contribution of COX-2 to tumorigenesis by Taketo and
colleagues, using an intestinal cancer model [32]. We have
adopted a parallel approach, crossing Cox-2 knockout mice
with the HER2/neu transgenic mouse mammary tumor virus
(MMTV)/neu deletion mutant (NDL) strain, to test the role of
COX-2 in breast cancer [40].
MMTV/NDL mice express a mutationally activated HER2/neu
transgene that drives formation of multiple DCIS-like tumors
in each mammary gland. These tumors subsequently
progress to invasive carcinomas and ultimately metastasize to
the lung, thus recapitulating the human disease [49]. Hence,
we employed the MMTV/NDL strain as a breast cancer model
system in which to examine the consequences of knocking
out  Cox-2. MMTV/NDL mice were crossed with Cox-2-
deficient mice, and tumor multiplicity was compared in
HER2/neu transgenic mice that were Cox-2 wild type,
heterozygous, and null. We found that tumor multiplicity was
significantly reduced in both Cox-2 heterozygous and null
animals relative to Cox-2 wild-type control animals
(P < 0.001; Figure 4a). Complete ablation of Cox-2 reduced
the mean tumor multiplicity by approximately 50%.
Additionally, an overall shift toward a higher proportion of
smaller tumors in Cox-2 null animals relative to Cox-2 wild-
type animals was observed (P = 0.02; Figure 4b), suggesting
that Cox-2 contributes not only to mammary tumor formation
but also to tumor growth. PGE2 levels in MMTV/NDL
mammary glands correlated with Cox-2 gene dosage. Thus,
PGE2 levels (ng/mg protein) in Cox-2 wild-type, hetero-
zygous, and null mammary tissues were 0.69 ± 0.11 (n =7 ) ,
0.53 ± 0.15 (n = 5;  P = 0.043), and 0.35 ± 0.07 (n =5 ;
P = 0.0001), respectively. These data provide the first
genetic evidence that Cox-2 contributes to HER2/neu-
induced mammary tumorigenesis [40].
Intriguingly, our Cox-2 knockout experiment also suggested a
novel role for Cox-2 in mammary gland vascularization.
Specifically, we observed a striking reduction in mammary
vasculature in Cox-2 null animals relative to wild-type controls.
Blood vessels were virtually absent from both dysplastic
regions and areas of normal looking epithelium (Figure 5a).
Consistent with the marked reduction in mammary vascula-
ture in Cox-2 null mammary tissues, the expression of several
angiogenesis-associated genes was decreased (Figure 5b),
including VEGF (which encodes vascular endothelial growth
factor), Ang1 and Ang2 (which encode Tie-2 ligands), and
Flk-1 and  Flt-1 (which encode vascular endothelial growth
factor receptors). Our data contrast with those obtained in
studies using mouse colorectal cancer models, which
suggest that Cox-2 contributes primarily to the growth and
vascularization of intestinal tumors beyond 1 mm in diameter
[50,51]. Thus, in addition to its previously described role in
tumor angiogenesis, Cox-2 may also contribute to blood
vessel formation in nontumorous mammary tissues.
Cyclooxygenase-2 acts as an oncogene in vivo
As described above, mammary tumorigenesis can be suppres-
sed by both genetic and pharmacologic ablation of Cox-2, thus
clearly identifying a role for COX-2 in breast neoplasia.
Furthermore, Hla and colleagues have provided definitive
evidence for in vivo oncogenic action of COX-2 through
generation of an MMTV/COX-2 transgenic mouse strain [41].
COX-2 over-expression in mouse mammary gland induced
tumor formation in more than 85% of multiparous mice [41].
Prior to visible tumor formation, COX-2 induced angiogenesis,
as evidenced by increased microvessel density and expression
of proangiogenic genes [52]. Furthermore, mammary gland
involution after weaning was delayed in transgenic animals
relative to wild-type littermates, with an accompanying
decrease in apoptosis [41]. Therefore, these data suggest that
COX-2 may drive tumor formation both by increasing
angiogenesis and by suppressing apoptotic cell death.
Together, these genetic and pharmacologic approaches
provide irrefutable evidence that COX-2 contributes to breast
cancer. Furthermore, these studies offer mechanistic insights
into the role of COX-2 in mammary neoplasia, indicating that
COX-2 is important for angiogenesis and may also play a
critical role in suppressing apoptosis. These observations are
Breast Cancer Research    Vol 9 No 4 Howe
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Figure 3
COX-2 expression in human breast cancer correlates with decreased
disease-free survival. Distant disease-free survival of breast cancer
patients was plotted as a function of cyclooxygenase (COX)-2
expression: score 0 = no COX-2 expression (n = 133); score
1 = weak COX-2 expression (n = 854); score 2 = moderate COX-2
expression (n = 511); and score 3 = strong COX-2 expression
(n = 78). Elevated expression of COX-2 protein correlated with
reduced survival (P < 0.0001; log rank test). Reproduced  from [26]
with permission from the American Association of Cancer Research.consistent with earlier studies in cell culture and in intestinal
tumor models. Multiple additional pro-tumorigenic roles have
been described for COX-derived prostanoids, including as
proproliferative stimuli, immune system depressants, and
promoters of cell invasiveness. COX-2 is also believed to
contribute to  the establishment of bone metastases. Of
particular relevance to breast cancer, PGs can increase
estrogen biosynthesis via upregulation of aromatase trans-
cription (discussed below). Thus, numerous mechanisms are
likely to contribute to the protumorigenic and metastasis-
promoting effects of eicosanoids.
The cyclooxygenase-aromatase connection
The relationship between COX and aromatase enzymes is
currently attracting considerable interest. The aromatase
cytochrome  P450, encoded by the CYP19 gene, is
responsible for estrogen biosynthesis and thus is extremely
relevant to breast carcinogenesis, since 60% to 70% of
breast cancers are hormone-dependent. Interestingly,
correlations between COX and aromatase expression have
been observed in human breast carcinomas [53,54]. These
correlations are thought to reflect a causal link, because PG
signaling can stimulate transcription of the CYP19 gene
[55-60]. PG-dependent CYP19 induction is achieved through
cAMP accumulation. At least two PGE2 receptor (EP)
isoforms signal by increasing adenylate cyclase activity [61],
and CYP19 is transcribed from cAMP-responsive promoters
in breast tumor-proximal stromal tissue. Thus, both paracrine
(tumor cell derived) and autocrine (stromally produced) PGE2
may contribute to aromatase upregulation in breast cancers.
Recent animal studies have demonstrated that mammary
aromatase activity is significantly reduced in Cox-2 knockout
mice, and, conversely, that aromatase expression and activity
are increased by transgenic COX-2 over-expression.
Together these datasets definitively establish that Cox-2 can
regulate aromatase in vivo in mammary tissues [56,62].
Peripheral aromatization is largely responsible for estrogen
production in postmenopausal women, and mammary
adipose tissue is a particularly important local estrogen
source. Therefore, regulation of mammary aromatase synthe-
sis by COX/PG signaling is most likely to be important in the
context of postmenopausal breast cancer. The ability of COX-
derived PGs to increase aromatase expression and hence
local estrogen levels may provide a partial explanation for
reports of reduced incidence of breast cancer associated
with NSAID use [5-12], because COX inhibition is predicted
to decrease mammary estrogen levels and hence restrict the
growth of estrogen-dependent tumors. This mechanism is
expected to be operative irrespective of COX-2 expression
status because COX-1 is constitutively expressed in human
breast tissues [21,25]. Importantly, the idea that both COX
isoforms can impact on tumorigenesis is supported by
genetic evidence obtained using Cox-1 and Cox-2 knockout
mouse strains [32,40,63,64]. Intriguingly, Neugut and
colleagues [65] have identified differential sensitivity of breast
cancers to NSAID-mediated protection according to
hormone receptor status. Specifically, they found that aspirin
use was associated with a decreased risk of hormone
receptor positive breast cancer, but did not affect the
incidence of hormone receptor-negative disease, in a
population-based case-control study. These data support the
concept that COX inhibition reduces mammary neoplasia at
least in part through suppression of estrogen biosynthesis.
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Figure 4
Knocking out Cox-2 reduces mammary tumorigenesis. Mouse mammary tumor virus (MMTV)/neu deletion mutant (NDL) mice, which express a
mammary-targeted HER2/neu transgene, were crossed with Cox-2-deficient mice, and mammary tumor formation was evaluated in age-matched
virgin MMTV/NDL females that were Cox-2 wild type (WT; n = 72), heterozygous (HET; n = 42), and null (NULL; n = 18). (a) Tumor multiplicity
was significantly reduced in Cox-2 deficient mice (data shown are mean ± SEM. *P < 0.001, by likelihood ratio test. (b) The percentage of tumors
in each of the indicated size categories was calculated for each genotype. The proportion of large tumors was significantly reduced in Cox-2
deficient MMTV/NDL animals relative to Cox-2 wild-type controls (P = 0.02). Reproduced with permission from [40].Cyclooxygenase/prostaglandin signaling as
an anticancer target
In combination, the data from COX-2 expression analyses,
NSAID-related epidemiology, animal studies, and in vitro
experiments strongly support a pro-tumorigenic role for COX-2
with respect to breast and other cancers. The considerable
weight of evidence linking COX/PG signaling with colorectal
neoplasia has stimulated evaluation of NSAIDs as preventive
agents in individuals at risk for colorectal cancer. Positive
results with conventional NSAIDs led to the development of
similar trials to test the efficacy of COXibs, based on the
expectation that these agents would have reduced gastro-
intestinal complications relative to conventional NSAIDs.
Importantly, COXibs were found to reduce the incidence of
both familial and sporadic disease, providing important proof-
of-principle for targeting COX/PG signaling [66-69]. Less
propitiously, some trials also identified increased cardio-
vascular risk associated with COXib use [70,71].
Cardiovascular toxicity of selective cyclooxygenase-2
inhibitors
The cardiovascular toxicity of COXibs has been ascribed to
their selective depression of prostacyclin levels [72]. Prosta-
cyclin (PGI2) derived from endothelial COX-2 confers
constraints on thrombogenesis, hypertension, and athero-
genesis. COX-2 inhibition decreases the cardioprotection
afforded by PGI2, but, in contrast, the prothrombotic effects
of thromboxane A2, emanating from COX-1 activity in
platelets, are unaffected. The cardiovascular toxicity of
COXibs decreases the desirability of using this class of drugs
in cancer prevention. Nevertheless, the demonstrated efficacy
of COXibs as anticancer agents identifies the COX/PG
signaling axis as an important target. Thus, it is incumbent on
us to identify alternative components of this signaling
pathway that offer safer targets for preventing cancer.
Alternative targets on the cyclooxygenase/
prostaglandin signaling axis
Several potential targets have been identified through
examination of eicosanoid metabolic pathways (Figure 1).
Importantly in this respect, substantial data support PGE2 as
being the predominant pro-tumorigenic prostanoid. Thus, it
seems reasonable to hypothesize that selective targeting of
PGE2 synthases or receptors might be useful with respect to
neoplasia, and more broadly for analgesia and anti-inflam-
matory applications. Substantial interest is focused on micro-
somal prostaglandin E synthase (mPGES)-1, which is up-
regulated in numerous human cancers, including breast
carcinomas [73,74]. mPGES-1 ablation does not increase
thrombogenesis or blood pressure [75], consistent with the
hypothesis that prostacyclin suppression is a key component
of COXib-induced cardiotoxicity. Thus, mPGES-1 may offer a
useful alternative target to COX-2 for combating inflammation
and cancer.
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Figure 5
Mammary gland vascularization is reduced in Cox-2 knockout mice. 
(a) Mammary gland tissue sections from age-matched virgin mouse
mammary tumor virus (MMTV)/neu deletion mutant (NDL) females that
were Cox-2 wild type (subpanels a to f) and Cox-2 null (subpanels g to
l) were subjected to anti-CD31 immunohistochemistry, and
counterstained with methyl green. Both the number and size of blood
vessels were strikingly reduced in Cox-2 null samples. (b) Expression
levels of angiogenesis-related genes were compared by quantitative
reverse transcription polymerase chain reaction in MMTV/NDL
mammary glands from Cox-2 wild-type (blue columns) and Cox-2 null
females (yellow columns). The height of the columns indicate means
normalized to the mean expression level of that gene in MMTV/NDL,
Cox-2 wild-type samples; the bars indicate the standard error.
Expression of VEGF, Ang1, and Flt1 was significantly reduced
(P = 0.016, 0.049 and 0.010, respectively). The average of log values
across all six genes for each mouse, representing a global effect, was
significantly higher in wild-type tissues than in null tissues at
P = 0.025. Reproduced with permission from [40].The role of individual PGE2 receptors (prostaglandin E
receptors [PTGERs] 1 to 4; more usually called EP1 to EP4)
in cancer is also under investigation. Expression of all four
EPs has been identified in mouse mammary tumors [29,52].
Genetic and pharmacologic ablation approaches have been
used to analyze the contributions of individual EPs to
tumorigenesis in multiple animal models. No single EP has
emerged as a clear favorite, with different receptors being
implicated depending on the experimental system [76]. EP1,
EP2, and EP4 all appear to have pro-tumorigenic activity in at
least one breast cancer model. Thus, it remains to be
established which PGE2 receptor(s) is the optimal candidate
for anticancer applications.
Enhancing PGE2 inactivation may provide an alternative
mechanism for ameliorating COX-associated neoplasia.
PGE2 is metabolized to relatively inactive 15-keto-PGs and
15-keto-lipoxins by the enzyme hydroxyprostaglandin dehydro-
genase 15-NAD, more commonly called 15-hydroxyprosta-
glandin dehydrogenase (15-PGDH; Figure 1). Strikingly,
reduced levels of 15-PGDH have been observed in multiple
tumors, including non-small-cell lung cancers, colorectal
carcinomas, and breast cancers, and substantial evidence
suggests that 15-PGDH acts as a tumor suppressor [77-82].
These observations suggest the intriguing possibility that
PGE2 signaling could be terminated by reversing epigenetic
inactivation of the 15-PGDH locus, and that this could offer a
novel approach to targeting PGE2-driven neoplasia.
Conclusions
The COX/PG signaling pathway offers a useful target for anti-
breast cancer strategies. COX-2 is over-expressed in a
significant proportion of invasive breast carcinomas, and at a
higher frequency in breast pre-cancers. Both pharmacologic
and genetic ablation of Cox-2 suppress experimental breast
cancer, and transgenic COX-2 over-expression drives tumor
formation. Together these data strongly support the validity of
COX/PG signaling as an anticancer target. The recently
appreciated cardiovascular toxicity of COXibs diminishes the
likely utility of this class of drugs for preventing cancer.
However, analysis of the pathways by which COX-derived
PGE2 drives tumorigenesis is expected to lead to identifica-
tion of novel drug targets for cancer treatment and prevention.
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